Cereno Scientific announces subscription commitments corresponding to 44 percent of outstanding warrants of series TO1
Cereno Scientific (XSAT: CRNO B) (“Cereno” or the “Company) today announced that it has received subscription commitments from a number of holders of warrants of series TO1, which includes members of the Company’s Board of Directors and its management group.
The subscription commitments received from the holders involves 13,446,926 warrants. And as previously announced on September 9, 2021, the Company has also received a subscription commitment from an investor that involves 1,713,537 warrants. The total amount of subscription commitments received thus involves 15,160,463 warrants, corresponding to 44 percent of the outstanding total.
The subscription commitments have been agreed in writing and no consideration is to be paid for the subscription commitments. The subscription commitments are not secured through bank guarantees, restricted funds, pledged assets or similar arrangements.
Further information about the warrants of series TO1 can be found on the Company’s website.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: [email protected]
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs named CS014 and CS585 targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.
Voluntis announces its results for the first half of 2021
Decline in commercial invoicing to€ 1.5 million and IFRS revenue to€ 1.3 million in H1 2021 Significant increase in deferred revenues to€ 11.6 million at 30 June 2021 Significant reduction in operational expenses as part of the strategic roadmap announced in Marc...
Voluntis annonce ses résultats du 1er semestre 2021
Recul des facturations commerciales à 1,5 million d'euros et du chiffre d'affaires IFRS à 1,3 million d'euros au 1er semestre 2021 ; Progression sensible des produits constatés d'avance à 11,6 millions d'euros au 30 juin 2021; Réductio...
Nanexa pausar NEX-18-studien
De måttliga hudreaktioner som uppkommit skiljer sig något från den milda reaktion som normalt uppstår efter administrering av 5-azacitidin. För att klargöra vad detta beror på gör Nanexa tillsammans med klinikerna en utredning inklusive biopsier av den påverkade huden. Utredningen väntas vara klar u...
Nanexa pauses NEX-18 study
The moderate skin reactions that have occured differ slightly from the mild reaction that normally occurs after the administration of 5-azacitidine. To clarify the cause, Nanexa together with the clinics is conducting an investigation including biopsies of the affected skin. The investigation is exp...